Pay in 4 interest-free payments of $6.21 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
This creates a broader metabolic effect than therapies that focus on appetite suppression alone
Randomised and non-randomised studies were included
Its not surprising, then, that results from Mercers National Survey of Employer-Sponsored Health Plans 2023 show that fewer than half of large employers (42% of those with 500 or more employees) currently cover GLP-1 medications for treatment of obesity, although another 19% say they are considering it
This creates blind spots for healthcare stakeholders and industry professionals due to lack of data visibility (e.g., claims) and aggregated reporting
Accessed June 6, 2023
US$ 25.61
US$ 27.56
US$ 21.30
